Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell; the sell-off returns

March 22, 2018 5:52pm

… Volatility jumps as volume dumps

As I had stated, “Sector equities stocks are still on track for continuous speculation.”

Pre-open indications: 0 HIT and 3 MISS (2 by pennies)

Q4 and FY17 numbers: Caladrius Biosciences (CLBS) ended the FY17 with a net loss of $16.2 M or -$1.78 per share with $60.1 M in cash and Cesca Therapeutics (KOOL) Q2 ended with a net loss of -$2.3 M or -$0.23 per share

Interpretation, insight and translation with an end-of-day recap of the sessions impact, settlement with an opinion of what could or should happen the next session thrown in.

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 49 min ago
RegMed Investors’ (RMi) pre-open: head and knee down

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.